The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines

@article{KostrzewaNowak2005TheRO,
  title={The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines},
  author={Dorota Kostrzewa-Nowak and Mark John Ingraham Paine and C. R. Wolf and Jolanta Tarasiuk},
  journal={British Journal of Cancer},
  year={2005},
  volume={93},
  pages={89 - 97}
}
Clinical usefulness of doxorubicin (DOX) is limited by the occurrence of multidrug resistance (MDR) associated with the presence of membrane transporters (e.g. P-glycoprotein, MRP1) responsible for the active efflux of drugs out of resistant cells. Doxorubicin is a well-known bioreductive antitumour drug. Its ability to undergo a one-electron reduction by cellular oxidoreductases is related to the formation of an unstable semiquionone radical and followed by the production of reactive oxygen… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Bioreductive drugs for cancer therapy: the search for tumor specificity.

  • International journal of radiation oncology, biology, physics
  • 1994
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL